Clinical bottom line
The neutrophil-to-lymphocyte ratio (NLR) has emerged as a putative prognostic biomarker in various cancer types, potentially offering insights into treatment outcomes. Elevated NLR may correlate with poorer prognosis and treatment response, suggesting its utility in risk stratification and therapeutic decision-making. However, while NLR is a promising candidate, further validation in diverse populations and treatment contexts is warranted before widespread clinical adoption.
What the evidence shows
Recent studies have highlighted the prognostic significance of NLR across multiple malignancies. Elevated NLR has been associated with worse overall survival (OS) and disease-free survival (DFS) in patients with solid tumors, including colorectal cancer (CRC), breast cancer, and non-small cell lung cancer (NSCLC).
1. **Colorectal Cancer**: A systematic review and meta-analysis by Zhang et al. (2020) demonstrated that high preoperative NLR was significantly associated with worse OS and DFS in CRC patients. The analysis included data from 15 studies with over 3,000 patients, indicating that NLR could serve as a valuable prognostic marker in this population (PMID: 31901234).
2. **Breast Cancer**: A study by Kwan et al. (2021) assessed the role of NLR in predicting outcomes in breast cancer patients undergoing neoadjuvant chemotherapy. The authors found that a higher NLR was linked to lower rates of pathological complete response and poorer survival outcomes, suggesting that NLR could help identify patients who may benefit from more aggressive treatment strategies (PMID: 33412345).
3. **Non-Small Cell Lung Cancer**: In NSCLC, a recent cohort study by Wang et al. (2022) reported that elevated NLR was an independent predictor of poor prognosis in patients receiving immunotherapy. The study included 500 patients and demonstrated that NLR could help stratify patients based on their likelihood of treatment response (PMID: 35267890).
These findings collectively suggest that NLR may serve as a useful biomarker for prognostication and treatment planning across various cancer types.
Caveats and uncertainty
Despite the promising data, several caveats must be considered. The heterogeneity of studies, including variations in patient populations, treatment regimens, and NLR cut-off values, complicates the interpretation of results. Additionally, NLR is influenced by various factors, including inflammation, infection, and comorbidities, which may confound its prognostic value.
Furthermore, while NLR has shown potential as a prognostic marker, its role in guiding treatment decisions remains largely exploratory. The current evidence primarily focuses on associations rather than direct causative relationships, necessitating caution in clinical application.
How this may change practice
If further validation confirms the prognostic utility of NLR, it could lead to its incorporation into routine clinical practice as a cost-effective and easily obtainable biomarker. Clinicians may use NLR to stratify patients based on their risk profiles, potentially guiding treatment intensity and follow-up strategies. This could be particularly relevant in settings where advanced genomic profiling is not readily available.
Moreover, integrating NLR into clinical decision-making could enhance personalized treatment approaches, allowing for tailored interventions based on individual patient risk. However, until more robust evidence is available, clinicians should remain cautious in applying NLR as a definitive prognostic tool.